Sinovac Biotech Co., Ltd
88
5
7
64
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
1.1%
1 terminated/withdrawn out of 88 trials
98.5%
+12.0% vs industry average
70%
62 trials in Phase 3/4
0%
0 of 64 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (88)
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months
Role: lead
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
Role: lead
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months
Role: lead
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months
Role: lead
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
Role: lead
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Role: lead
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
Role: lead
Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine
Role: lead
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
Role: lead
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women
Role: lead
Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Role: lead
Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
Role: lead
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial
Role: lead
Booster Dose of sIPV Co-administered With MMR and HepA-I.
Role: lead
Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
Role: collaborator
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
Role: lead
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
Role: lead
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
Role: lead
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
Role: lead
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
Role: lead